Wedmont Private Capital’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$600K Buy
3,012
+104
+4% +$19.9K 0.02% 495
2026
Q1
$523K Buy
2,908
+115
+4% +$21.2K 0.02% 480
2025
Q4
$522K Buy
2,793
+113
+4% +$18.5K 0.02% 454
2025
Q3
$408K Buy
2,680
+490
+22% +$66.2K 0.02% 526
2025
Q2
$291K Buy
2,190
+81
+4% +$10.1K 0.01% 582
2025
Q1
$243K Sell
2,109
-1,561
-43% -$223K 0.01% 579
2024
Q4
$546K Buy
3,670
+2,392
+187% +$403K 0.03% 352
2024
Q3
$234K Sell
1,278
-1,373
-52% -$287K 0.01% 586
2024
Q2
$610K Buy
2,651
+238
+10% +$51.7K 0.04% 298
2024
Q1
$498K Buy
2,413
+446
+23% +$104K 0.04% 320
2023
Q4
$507K Buy
1,967
+743
+61% +$182K 0.04% 301
2023
Q3
$323K Buy
1,224
+47
+4% +$12.6K 0.03% 355
2023
Q2
$328K Buy
1,177
+142
+14% +$42.3K 0.04% 359
2023
Q1
$293K Sell
1,035
-128
-11% -$35.4K 0.04% 355
2022
Q4
$325K Buy
1,163
+253
+28% +$71.5K 0.05% 317
2022
Q3
$243K Buy
+910
New +$193K 0.05% 312

Other funds holding BIIB

Wedmont Private Capital's BIIB Position: Q2 2026 in Review

Wedmont Private Capital increased its Biogen (BIIB) stake by 3.6% in Q2 2026, buying an estimated $19.9K and bringing the position to 3,012 shares worth $600K. The position accounts for 0.02% of the portfolio, ranked #495.

Wedmont Private Capital first reported a position in BIIB in Q3 2022 and has held it in 16 quarters since. The position peaked at $610K in Q2 2024. 269 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Wedmont Private Capital held 3,012 shares of Biogen worth $600K as of Q2 2026.
  • Wedmont Private Capital bought 104 Biogen shares in Q2 2026, an estimated $19.9K.
  • Biogen made up 0.02% of Wedmont Private Capital's portfolio in Q2 2026, its #495 holding.
  • Wedmont Private Capital first reported a position in Biogen in Q3 2022 and has held it in 16 quarters since.
  • Wedmont Private Capital's Biogen position peaked at $610K in Q2 2024.
  • 269 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.